COHORT STUDY:

N/A

OTHER REFERENCE(S):

1: Association of miR-145 With Statin-Induced Skeletal Muscle Toxicity in Human Rhabdomyosarcoma RD Cells.

[Saito Shun,Nakanishi Takeo,Shirasaki Yuma,Nakajima Miki,Tamai Ikumi]
J Pharm Sci.2017 Sep;106(9):2873-2880. doi: 10.1016/j.xphs.2017.04.005. Epub 2017 Apr 21. PMID: 28438533

2: [Safety of statins].

[Oscanoa Espinoza Teodore J,Paredes-Pérez Napoleon,Lizaraso-Soto Frank]
Rev Fac Cien Med Univ Nac Cordoba.2016;73(4):263-278. PMID: 28152368

3: Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information.

[Kim Soo-Jin,Yoshikado Takashi,Ieiri Ichiro,Maeda Kazuya,Kimura Miyuki,Irie Shin,Kusuhara Hiroyuki,Sugiyama Yuichi]
Drug Metab Dispos.2016 Oct;44(10):1622-32. doi: 10.1124/dmd.116.070276. Epub 2016 Jul 25. PMID: 27457785

4: Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment.

[Zhao Shuiping,Wang Fang,Dai Yangyang,Lin Ling,Tong Qiguang,Liao Yuhua,Yin Yuehui,Wang Guang,Yan Yafei,Li Xiaodong,Wang Daowen,Wei Ping,Cheng Xingbo,Xie Qiang,Sun Yuemin,Fu Guosheng,Huang Hongman,Dong Yugang,Liu Jianxiong,Yan Jianling,Yan Li,Cui Shiwei,Liu Xuebo,Li Zhaoping,Chen Hong,Hu Taohong,Gong Hui]
Int J Cardiol.2016 Oct 15;221:832-6. doi: 10.1016/j.ijcard.2016.06.234. Epub 2016 Jun 29. PMID: 27434354

5: A benefit-risk assessment model for statins using multicriteria decision analysis based on a discrete choice experiment in Korean patients.

[Byun Ji-Hye,Kwon Sun-Hong,Ha Ji-Hye,Lee Eui-Kyung]
Ther Clin Risk Manag.2016 Jun 13;12:965-74. doi: 10.2147/TCRM.S100438. eCollection 2016. PMID: 27358567

6: Absence of anti-HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy.

[Floyd James S,Brody Jennifer A,Tiniakou Eleni,Psaty Bruce M,Mammen Andrew]
Muscle Nerve.2016 Jun;54(1):142-4. doi: 10.1002/mus.25127. PMID: 27038110

7: Successful reintroduction of statin therapy after statin-associated rhabdomyolysis.

[Simons Janet E,Holbrook Anne M,Don-Wauchope Andrew C]
J Clin Lipidol.2015 Jul-Aug;9(4):594-6. doi: 10.1016/j.jacl.2015.03.005. Epub 2015 Mar 28. PMID: 26228678

8: Inhibition of prenyltransferase activity by statins in both liver and muscle cell lines is not causative of cytotoxicity.

[Gee Rowena H,Spinks Jenny N,Malia Jason M,Johnston Jonathan D,Plant Nick J,Plant Kathryn E]
Toxicology.2015 Mar 2;329:40-8. doi: 10.1016/j.tox.2015.01.005. Epub 2015 Jan 8. PMID: 25578243

9: Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions.

[Tornio A,Filppula A M,Kailari O,Neuvonen M,Nyrönen T H,Tapaninen T,Neuvonen P J,Niemi M,Backman J T]
Clin Pharmacol Ther.2014 Oct;96(4):498-507. doi: 10.1038/clpt.2014.141. Epub 2014 Jun 27. PMID: 24971633

10: A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment.

[Gagne Joshua J,Wang Shirley V,Rassen Jeremy A,Schneeweiss Sebastian]
Pharmacoepidemiol Drug Saf.2014 Jun;23(6):619-27. doi: 10.1002/pds.3616. Epub 2014 Apr 30. PMID: 24788694

11: Safety of statins.

[Maji Debasish,Shaikh Shehla,Solanki Dharmesh,Gaurav Kumar]
Indian J Endocrinol Metab.2013 Jul;17(4):636-46. doi: 10.4103/2230-8210.113754. PMID: 23961479

12: OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.

[Tamraz Bani,Fukushima Hisayo,Wolfe Alan R,Kaspera Rüdiger,Totah Rheem A,Floyd James S,Ma Benjamin,Chu Catherine,Marciante Kristin D,Heckbert Susan R,Psaty Bruce M,Kroetz Deanna L,Kwok Pui-Yan]
Pharmacogenet Genomics.2013 Jul;23(7):355-64. doi: 10.1097/FPC.0b013e3283620c3b. PMID: 23652407

13: Characterization of Statin-Associated Myopathy Case Reports in Thailand Using the Health Product Vigilance Center Database.

[Boonmuang Pornwalai,Nathisuwan Surakit,Chaiyakunapruk Nathorn,Suwankesawong Wimon,Pokhagul Pattreya,Teerawattanapong Nattawat,Supsongserm Pairin]
Drug Saf.2013 Sep;36(9):779-87. doi: 10.1007/s40264-013-0055-5. PMID: 23615756

14: Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting.

[Cziraky Mark J,Willey Vincent J,McKenney James M,Kamat Siddhesh A,Fisher Maxine D,Guyton John R,Jacobson Terry A,Davidson Michael H]
J Clin Lipidol.2013 Mar-Apr;7(2):102-8. doi: 10.1016/j.jacl.2012.06.006. Epub 2012 Jul 3. PMID: 23415428

15: Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system.

[Gagne J J,Glynn R J,Rassen J A,Walker A M,Daniel G W,Sridhar G,Schneeweiss S]
Clin Pharmacol Ther.2012 Jul;92(1):80-6. doi: 10.1038/clpt.2011.369. Epub 2012 May 16. PMID: 22588606

16: A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel.

[Floyd J S,Kaspera R,Marciante K D,Weiss N S,Heckbert S R,Lumley T,Wiggins K L,Tamraz B,Kwok P-Y,Totah R A,Psaty B M]
Clin Pharmacol Ther.2012 May;91(5):896-904. doi: 10.1038/clpt.2011.295. Epub 2012 Mar 14. PMID: 22419147

17: Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules.

[Gagne Joshua J,Rassen Jeremy A,Walker Alexander M,Glynn Robert J,Schneeweiss Sebastian]
Epidemiology.2012 Mar;23(2):238-46. doi: 10.1097/EDE.0b013e3182459d7d. PMID: 22266893

18: Induction of the C-terminal proteolytic cleavage of AβPP by statins.

[Descamps Olivier,Zhang Qiang,John Varghese,Bredesen Dale E]
J Alzheimers Dis.2011;25(1):51-7. doi: 10.3233/JAD-2011-101857. PMID: 21422530

19: Cerivastatin, genetic variants, and the risk of rhabdomyolysis.

[Marciante Kristin D,Durda Jon P,Heckbert Susan R,Lumley Thomas,Rice Ken,McKnight Barbara,Totah Rheem A,Tamraz Bani,Kroetz Deanna L,Fukushima Hisayo,Kaspera Rüdiger,Bis Joshua C,Glazer Nicole L,Li Guo,Austin Thomas R,Taylor Kent D,Rotter Jerome I,Jaquish Cashell E,Kwok Pui-Yan,Tracy Russell P,Psaty Bruce M]
Pharmacogenet Genomics.2011 May;21(5):280-8. doi: 10.1097/FPC.0b013e328343dd7d. PMID: 21386754

20: Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis.

[Kaspera Rüdiger,Naraharisetti Suresh B,Tamraz Bani,Sahele Tariku,Cheesman Matthew J,Kwok Pui-Yan,Marciante Kristin,Heckbert Susan R,Psaty Bruce M,Totah Rheem A]
Pharmacogenet Genomics.2010 Oct;20(10):619-29. doi: 10.1097/FPC.0b013e32833ecace. PMID: 20739906

21: Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.

[Strandell Johanna,Bate Andrew,Hägg Staffan,Edwards I Ralph]
Br J Clin Pharmacol.2009 Sep;68(3):427-34. doi: 10.1111/j.1365-2125.2009.03473.x. PMID: 19740401

22: [Metabolic rhabdomyolysis during statin therapy].

[Vergely N,Leca V,Antoine J-C,Germain N,Khalfallah Y,Estour B]
Rev Med Interne.2009 Aug;30(8):711-3. doi: 10.1016/j.revmed.2008.10.336. Epub 2009 May 5. PMID: 19419805

23: [Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil].

[Huić Mirjana,Anić Branimir,Cikes Nada,Bosnić Dubravka,Sentić Mirna,Markeljević Jasenka,Mayer Miroslav,Pazanin Leo]
Lijec Vjesn.2002 Mar-Apr;124(3-4):73-6. PMID: 18956824

24: Severe obstructive sleep apnea after cerivastatin therapy: a case report.

[Ebben Matthew R,Sethi Nitin K,Spielman Arthur J]
J Clin Sleep Med.2008 Jun 15;4(3):255-6. PMID: 18595439

25: Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.

[Motola Domenico,Vargiu Antonio,Leone Roberto,Conforti Anita,Moretti Ugo,Vaccheri Alberto,Velo Giampaolo,Montanaro Nicola]
Drug Saf.2008;31(7):609-16. PMID: 18558794

26: Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.

[McAdams Mara,Staffa Judy,Dal Pan Gerald]
Pharmacoepidemiol Drug Saf.2008 Mar;17(3):229-39. doi: 10.1002/pds.1535. PMID: 18175291

27: Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use.

[Holoshitz Noa,Alsheikh-Ali Alawi A,Karas Richard H]
Am J Cardiol.2008 Jan 1;101(1):95-7. Epub 2007 Nov 26. PMID: 18157972

28: Early detection of adverse drug events within population-based health networks: application of sequential testing methods.

[Brown Jeffrey S,Kulldorff Martin,Chan K Arnold,Davis Robert L,Graham David,Pettus Parker T,Andrade Susan E,Raebel Marsha A,Herrinton Lisa,Roblin Douglas,Boudreau Denise,Smith David,Gurwitz Jerry H,Gunter Margaret J,Platt Richard]
Pharmacoepidemiol Drug Saf.2007 Dec;16(12):1275-84. PMID: 17955500

29: Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.

[Pariente Antoine,Gregoire Fleur,Fourrier-Reglat Annie,Haramburu Françoise,Moore Nicholas]
Drug Saf.2007;30(10):891-8. PMID: 17867726

30: [Rhabdomyolysis induced by statins].

[Hamano Tadanori,Muto Tatsuro,Kuriyama Masaru]
Nihon Naika Gakkai Zasshi.2007 Aug 10;96(8):1646-51. PMID: 17802715

31: CYP2D6*4 polymorphism is associated with statin-induced muscle effects.

[Frudakis Tony N,Thomas Matthew J,Ginjupalli Siva N,Handelin Barbara,Gabriel Richard,Gomez Hector J]
Pharmacogenet Genomics.2007 Sep;17(9):695-707. PMID: 17700359

32: Preventive effects of bicarbonate on cerivastatin-induced apoptosis.

[Kobayashi Masaki,Kaido Fumie,Kagawa Toshiki,Itagaki Shirou,Hirano Takeshi,Iseki Ken]
Int J Pharm.2007 Aug 16;341(1-2):181-8. Epub 2007 Apr 24. PMID: 17553641

33: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.

[Neuvonen Pertti J,Niemi Mikko,Backman Janne T]
Clin Pharmacol Ther.2006 Dec;80(6):565-81. PMID: 17178259

34: Risks associated with statin therapy: a systematic overview of randomized clinical trials.

[Kashani Amir,Phillips Christopher O,Foody JoAnne M,Wang Yongfei,Mangalmurti Sandeep,Ko Dennis T,Krumholz Harlan M]
Circulation.2006 Dec 19;114(25):2788-97. Epub 2006 Dec 11. PMID: 17159064

35: Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present.

[McClure David L,Valuck Robert J,Glanz Morton,Hokanson John E]
Pharmacoepidemiol Drug Saf.2007 Feb;16(2):132-43. PMID: 17072896

36: Rosuvastatin: an independent analysis of risks and benefits.

[Zipes Douglas P,Zvaifler Nathan J,Glassock Richard J,Gilman Sid,Muñoz Alvaro,Gogolak Victor,Gordis Leon,Dedon Peter C,Guengerich Frederick P,Wasserman Stephen I,Witztum Joseph L,Wogan Gerald N]
MedGenMed.2006 Jun 14;8(2):73. PMID: 16926812

37: Statin-induced myopathy: the two faces of Janus.

[Arora Rohit,Liebo Max,Maldonado Frank]
J Cardiovasc Pharmacol Ther.2006 Jun;11(2):105-12. PMID: 16891287

38: Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.

[Shitara Yoshihisa,Sugiyama Yuichi]
Pharmacol Ther.2006 Oct;112(1):71-105. Epub 2006 May 22. PMID: 16714062

39: Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs.

[Roth-Cline Michelle D]
Circulation.2006 May 9;113(18):2253-9. PMID: 16684875

40: Statin safety: an assessment using an administrative claims database.

[Cziraky Mark J,Willey Vincent J,McKenney James M,Kamat Siddhesh A,Fisher Maxine D,Guyton John R,Jacobson Terry A,Davidson Michael H]
Am J Cardiol.2006 Apr 17;97(8A):61C-68C. Epub 2006 Jan 30. PMID: 16581331

41: Statin safety: a systematic review.

[Law Malcolm,Rudnicka Alicja R]
Am J Cardiol.2006 Apr 17;97(8A):52C-60C. Epub 2006 Feb 3. PMID: 16581329

42: Statin safety: lessons from new drug applications for marketed statins.

[Jacobson Terry A]
Am J Cardiol.2006 Apr 17;97(8A):44C-51C. Epub 2006 Feb 2. PMID: 16581328

43: Statin safety: an appraisal from the adverse event reporting system.

[Davidson Michael H,Clark John A,Glass Lucas M,Kanumalla Anju]
Am J Cardiol.2006 Apr 17;97(8A):32C-43C. Epub 2006 Feb 3. PMID: 16581327

44: [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].

[Saito Mitsuo,Hirata-Koizumi Mutsuko,Miyake Shinji,Hasegawa Ryuichi]
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku.2005;(123):41-5. PMID: 16541751

45: Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein.

[Matzno Sumio,Yasuda Shinya,Juman Sachiko,Yamamoto Yukiko,Nagareya-Ishida Noriko,Tazuya-Murayama Keiko,Nakabayashi Toshikatsu,Matsuyama Kenji]
J Pharm Pharmacol.2005 Nov;57(11):1475-84. PMID: 16259781

46: [Severe muscle disorders associated with statins: analysis of cases notified in France up to the end of February 2002 and data concerning the risk profile of cerivastatin].

[Andréjak Michel,Gras Valérie,Caron Jacques]
Therapie.2005 May-Jun;60(3):299-304. PMID: 16128274

47: Safety of high-dose atorvastatin therapy.

[Waters David D]
Am J Cardiol.2005 Sep 5;96(5A):69F-75F. PMID: 16126026

48: Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins.

[Morikawa Shigeru,Murakami Takeshi,Yamazaki Hiroyuki,Izumi Akashi,Saito Yasushi,Hamakubo Takao,Kodama Tatsuhiko]
J Atheroscler Thromb.2005;12(3):121-31. PMID: 16020911

49: The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis.

[Alsheikh-Ali Alawi A,Ambrose Marietta S,Kuvin Jeffrey T,Karas Richard H]
Circulation.2005 Jun 14;111(23):3051-7. Epub 2005 May 23. PMID: 15911706

50: Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.

[Ozaki H,Ishikawa C T,Ishii T,Toyoda A,Murano T,Miyashita Y,Shirai K]
J Clin Pharm Ther.2005 Apr;30(2):189-92. PMID: 15811174

51: Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.

[Schachter Michael]
Fundam Clin Pharmacol.2005 Feb;19(1):117-25. PMID: 15660968

52: Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis".

[Piorkowski Joseph D]
JAMA.2004 Dec 1;292(21):2655-7; discussion 2658-9. Epub 2004 Nov 22. PMID: 15572725

53: Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint.

[Strom Brian L]
JAMA.2004 Dec 1;292(21):2643-6. Epub 2004 Nov 22. PMID: 15572722

54: Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.

[Psaty Bruce M,Furberg Curt D,Ray Wayne A,Weiss Noel S]
JAMA.2004 Dec 1;292(21):2622-31. Epub 2004 Nov 22. PMID: 15572720

55: Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.

[Graham David J,Staffa Judy A,Shatin Deborah,Andrade Susan E,Schech Stephanie D,La Grenade Lois,Gurwitz Jerry H,Chan K Arnold,Goodman Michael J,Platt Richard]
JAMA.2004 Dec 1;292(21):2585-90. Epub 2004 Nov 22. PMID: 15572716

56: Overexpression of neural cell adhesion molecule in regenerative muscle fibers in 3-hydroxy-3-methylglutaryl coenzyme: A reductase inhibitor-induced rhabdomyolysis.

[Salarieh Afshin,Soler Alejandro Peralta,Axiotis Constantine A]
Appl Immunohistochem Mol Morphol.2004 Sep;12(3):234-9. PMID: 15551737

57: Rosuvastatin: new preparation. Opt for statins with evidence of efficacy on clinical outcome.

Prescrire Int.2004 Aug;13(72):132-4. PMID: 15532136

58: Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone.

[Johnson Timothy E,Zhang Xiaohua,Bleicher Kimberly B,Dysart Gary,Loughlin Amy F,Schaefer William H,Umbenhauer Diane R]
Toxicol Appl Pharmacol.2004 Nov 1;200(3):237-50. PMID: 15504460

59: Rosuvastatin safety: lessons from the FDA review and post-approval surveillance.

[Davidson Michael H]
Expert Opin Drug Saf.2004 Nov;3(6):547-57. PMID: 15500414

60: Risk of adverse events with fibrates.

[Alsheikh-Ali Alawi A,Kuvin Jeffrey T,Karas Richard H]
Am J Cardiol.2004 Oct 1;94(7):935-8. PMID: 15464682

61: A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin.

[Ishikawa Chikako,Ozaki Hiroshi,Nakajima Toshiaki,Ishii Toshihiro,Kanai Saburo,Anjo Saeko,Shirai Kohji,Inoue Ituro]
J Hum Genet.2004;49(10):582-5. Epub 2004 Sep 9. PMID: 15365880

62: Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors.

[Vermes Andras,Vermes Istvan]
Am J Cardiovasc Drugs.2004;4(4):247-55. PMID: 15285699

63: Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.

[Chang Jennie T,Staffa Judy A,Parks Mary,Green Lanh]
Pharmacoepidemiol Drug Saf.2004 Jul;13(7):417-26. PMID: 15269925

64: The cerivastatin withdrawal crisis: a "post-mortem" analysis.

[Maggini Marina,Raschetti Roberto,Traversa Giuseppe,Bianchi Clara,Caffari Bruno,Da Cas Roberto,Panei Pietro]
Health Policy.2004 Aug;69(2):151-7. PMID: 15212862

65: Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors.

[Jamal Shelina M,Eisenberg Mark J,Christopoulos Stavroula]
Am Heart J.2004 Jun;147(6):956-65. PMID: 15199341

66: Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals.

[Dugué A,Bagheri H,Lapeyre-Mestre M,Tournamille J F,Sailler L,Dedieu G,Salvayre R,Thouvenot J P,Massip P,Montastruc J L]
Eur J Clin Pharmacol.2004 Jun;60(4):285-92. Epub 2004 Apr 28. PMID: 15114428

67: Early detection of drug interactions utilizing a computerized drug prescription handling system-focus on cerivastatin-gemfibrozil.

[Morera Tomás,Gervasini Guillermo,Carrillo Juan A,Benitez Julio]
Eur J Clin Pharmacol.2004 Feb;59(12):917-21. Epub 2004 Jan 21. PMID: 14735257

68: Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats.

[Schaefer William H,Lawrence Jeffery W,Loughlin Amy F,Stoffregen Dana A,Mixson Lori A,Dean Dennis C,Raab Conrad E,Yu Nathan X,Lankas George R,Frederick Clay B]
Toxicol Appl Pharmacol.2004 Jan 1;194(1):10-23. PMID: 14728975

69: Ca2+-releasing effect of cerivastatin on the sarcoplasmic reticulum of mouse and rat skeletal muscle fibers.

[Inoue Ryotaku,Tanabe Mitsuo,Kono Keita,Maruyama Kei,Ikemoto Takaaki,Endo Makoto]
J Pharmacol Sci.2003 Nov;93(3):279-88. PMID: 14646245

70: Effectiveness of statin-gemfibrozil combination therapy in patients with mixed hyperlipidemia: experience of a community lipid clinic and safety review from the literature.

[Shammas Nicholas W,Kapalis Matthew J,Deckert Judi,Harris Melodee,Dippel Eric J,Labroo Ajay,McKinney Dawn]
Prev Cardiol.2003 Fall;6(4):189-94. PMID: 14605512

71: The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk.

[Corsini Alberto]
Cardiovasc Drugs Ther.2003 May;17(3):265-85. PMID: 14574085

72: Cerivastatin monotherapy-induced muscle weakness, rhabdomyolysis and acute renal failure.

[Bakri Rashed,Wang Joe,Wierzbicki Anthony S,Goldsmith David]
Int J Cardiol.2003 Sep;91(1):107-9. PMID: 12957739

73: Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor.

[Kajinami Kouji,Takekoshi Noboru,Saito Yasushi]
Cardiovasc Drug Rev.2003 Fall;21(3):199-215. PMID: 12931254

74: Controversy surrounding the safety of cerivastatin.

[Davidson Michael H]
Expert Opin Drug Saf.2002 Sep;1(3):207-12. PMID: 12904136

75: Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era.

[Jacobson Terry A]
Expert Opin Drug Saf.2003 May;2(3):269-86. PMID: 12904106

76: [Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis].

[Zeitlinger Markus,Müller Markus]
Wien Med Wochenschr.2003;153(11-12):250-4. PMID: 12879633

77: Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis.

[Matzno Sumio,Tazuya-Murayama Keiko,Tanaka Hiromi,Yasuda Shinya,Mishima Motohiro,Uchida Takahiro,Nakabayashi Toshikatsu,Matsuyama Kenji]
J Pharm Pharmacol.2003 Jun;55(6):795-802. PMID: 12841940

78: [Adverse effects of statins].

[Andréjak Michel,Gras Valérie,Massy Ziad A,Caron Jacques]
Therapie.2003 Jan-Feb;58(1):77-83. PMID: 12822204

79: Statin-fibrate combination: therapy for hyperlipidemia: a review.

[Wierzbicki A S,Mikhailidis D P,Wray R,Schacter M,Cramb R,Simpson W G,Byrne C B]
Curr Med Res Opin.2003;19(3):155-68. PMID: 12814127

80: Statin-associated myopathy.

[Thompson Paul D,Clarkson Priscilla,Karas Richard H]
JAMA.2003 Apr 2;289(13):1681-90. PMID: 12672737

81: [Information regarding adverse drug effects and treatment indications ("package inserts") exemplified by cervistatin (Lipobay)].

[Braun Robert N,Halhuber Max J,Hitzenberger Gerhart]
Wien Med Wochenschr.2003;153(3-4):80-2. PMID: 12658968

82: How a statin might destroy a drug company.

Lancet.2003 Mar 8;361(9360):793. PMID: 12642039

83: Safety and statin therapy: reconsidering the risks and benefits.

[Gotto Antonio M]
Arch Intern Med.2003 Mar 24;163(6):657-9. PMID: 12639194

84: Statins and myotoxicity.

[Yan Lin,Lan Fen,Wang Zhen-Gang,Li You-Ping]
Trends Pharmacol Sci.2003 Mar;24(3):113-4. PMID: 12628352

85: Bayer is forced to release documents over withdrawal of cerivastatin.

[Marwick Charles]
BMJ.2003 Mar 8;326(7388):518. PMID: 12623898

86: [Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors].

[Sparing R,Sellhaus B,Noth J,Block F]
Nervenarzt.2003 Feb;74(2):167-71. PMID: 12596018

87: Statins and myotoxicity.

[Farmer John A]
Curr Atheroscler Rep.2003 Mar;5(2):96-100. PMID: 12573193

88: Myoglobinuria and COX deficiency in a patient taking cerivastatin and gemfibrozil.

[Arenas J,Fernández-Moreno M A,Molina J A,Fernández V,del Hoyo P,Campos Y,Calvo P,Martín M A,García A,Moreno T,Martínez-Salio A,Börnstein B,Bermejo F,Cabello A,Garesse R]
Neurology.2003 Jan 14;60(1):124-6. PMID: 12525734

89: Gemfibrozil greatly increases plasma concentrations of cerivastatin.

[Backman Janne T,Kyrklund Carl,Neuvonen Mikko,Neuvonen Pertti J]
Clin Pharmacol Ther.2002 Dec;72(6):685-91. PMID: 12496749

90: Labelling and 'Dear Doctor' letters: are they noncommittal?

[van Grootheest A C Kees,Edwards I Ralph]
Drug Saf.2002;25(15):1051-5. PMID: 12452731

91: Safety considerations for statins.

[Bolego Chiara,Baetta Roberta,Bellosta Stefano,Corsini Alberto,Paoletti Rodolfo]
Curr Opin Lipidol.2002 Dec;13(6):637-44. PMID: 12441888

92: Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction.

[Kind Amy Haavisto,Zakowski Laura J,McBride Patrick E]
WMJ.2002;101(7):53-6. PMID: 12426921

93: Rhabdomyolysis and cerivastatin: was it a problem of dose?

[Kalaria Dipen,Wassenaar Willem]
CMAJ.2002 Oct 1;167(7):737. PMID: 12389822

94: HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions.

[Huynh T,Cordato D,Yang F,Choy T,Johnstone K,Bagnall F,Hitchens N,Dunn R]
Intern Med J.2002 Sep-Oct;32(9-10):486-90. PMID: 12380704

95: Cerivastatin induces rhabdomyolysis and acute renal failure.

[Di Paolo Nicola,Monaci Giulio,Cappelletti Francesca,Di Paolo Marco,Verzuri M Serena]
Nephron.2002;92(3):751. PMID: 12372976

96: Cerivastatin and gemfibrozil-induced cardiac rhabdomyolysis.

[Su Mark,Hoffman Robert S,Flomenbaum Mark]
Am J Forensic Med Pathol.2002 Sep;23(3):305-6. PMID: 12198364

97: Contacting patients of a Pakistani hospital about a drug recall.

[Zaidi Syed Tabish Razi,Sheikh Abdul Latif,Raza Syed Shamim]
Am J Health Syst Pharm.2002 Aug 15;59(16):1569. PMID: 12185834

98: The myotoxicity of statins.

[Evans Marc,Rees Alan]
Curr Opin Lipidol.2002 Aug;13(4):415-20. PMID: 12151857

99: Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?

[Evans Marc,Rees Alan]
Drug Saf.2002;25(9):649-63. PMID: 12137559

100: [Rhabdomyolysis, acute renal failure and use of cerivastatin combined with gemfibrozil. New evidence].

[SantaCruz P L,González A,León M E,Fernández M Y]
Nefrologia.2002;22(3):301-2. PMID: 12123135

101: Statins and muscles: what price glory?

[Hayem Gilles]
Joint Bone Spine.2002 May;69(3):249-51. PMID: 12102269

102: Severe rhabdomyolysis related to cerivastatin without gemfibrozil.

[Hyman David J,Henry Andrea,Taylor Addison]
Ann Intern Med.2002 Jul 2;137(1):74. PMID: 12093260

103: Rhabdomyolysis-related renal tubular damage studied by proton nuclear magnetic resonance spectroscopy of urine.

[Bairaktari Eleni,Seferiadis Konstantin,Liamis George,Psihogios Nikolaos,Tsolas Orestes,Elisaf Moses]
Clin Chem.2002 Jul;48(7):1106-9. PMID: 12089184

104: Rhabdomyolysis associated with cerivastatin: six cases within 3 months at one hospital.

[Lucas Robert A,Weathersby B Blake,Rocco Vito K,Pepper J Michael,Butler Kerry L]
Pharmacotherapy.2002 Jun;22(6):771-4. PMID: 12066968

105: Rhabdomyolysis from high-dose cerivastatin therapy.

[Feeney Eion R,Calissi Piera T,Pylypchuk George B]
Ann Pharmacother.2002 Jun;36(6):1106. PMID: 12058707

106: Pharmacological interactions of statins.

[Paoletti Rodolfo,Corsini Alberto,Bellosta Stefano]
Atheroscler Suppl.2002 May;3(1):35-40. PMID: 12044584

107: [Rhabdomyolisis associated with cerivastatin and cyclosporine combination therapy].

[Nicolás De Prado Isabel,Miras López Manuel,Morán Sánchez Senador,Mercader Martínez José]
Med Clin (Barc).2002 May 18;118(18):716-7. PMID: 12042140

108: Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

[Williams David,Feely John]
Clin Pharmacokinet.2002;41(5):343-70. PMID: 12036392

109: Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen.

[Marsà Carretero Mireia,Alos Manrique Cristina,Valles Callol Joan-Antoni]
Br J Gen Pract.2002 Mar;52(476):235-6. PMID: 12030671

110: Statin stories.

Diabetes Obes Metab.2002 Mar;4(2):138. PMID: 11993442

111: Bayer voluntarily withdraws Baycol.

AWHONN Lifelines.2001 Oct-Nov;5(5):21. PMID: 11982285

112: Statin safety.

[Foxton J]
Nurs Stand.2001 Sep 19-25;16(1):20. PMID: 11977679

113: Cerivastatin-induced rhabdomyolysis: 11 case reports.

[Ravnan Susan L,Locke Christy,Yee William P,Haase Kelli]
Pharmacotherapy.2002 Apr;22(4):533-7. PMID: 11939690

114: Severe rhabdomyolysis and cerivastatin-gemfibrozil combination therapy.

[Roca Bernardino,Calvo Begoña,Monferrer Rafael]
Ann Pharmacother.2002 Apr;36(4):730-1. PMID: 11936088

115: Risperidone and severe cerivastatin-induced rhabdomyolysis.

[Giner V,Muñoz R,Redón J]
J Intern Med.2002 Feb;251(2):177-8. PMID: 11905593

116: Lipid-lowering drugs (statins), cholesterol, and coenzyme Q10. The Baycol case--a modern Pandora's box.

[Bliznakov E G]
Biomed Pharmacother.2002 Feb;56(1):56-9. PMID: 11905511

117: [Myotoxicity and rhabdomyolisis due to statins].

[Cohen L H]
Ned Tijdschr Geneeskd.2002 Mar 2;146(9):440-1; author reply 441. PMID: 11901950

118: [Massive rhabdomyolysis associated with the use of cerivastatin monotherapy].

[Vera M,Pou M,Botey A,Cases A]
Nefrologia.2001;21(6):613-4. PMID: 11881437

119: Myopathy and rhabdomyolysis with lipid-lowering drugs.

[Hodel Christian]
Toxicol Lett.2002 Mar 10;128(1-3):159-68. PMID: 11869826

120: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient.

[Sica Domenic A,Gehr Todd W B]
Curr Opin Nephrol Hypertens.2002 Mar;11(2):123-33. PMID: 11856903

121: FDA adverse event reports on statin-associated rhabdomyolysis.

[Omar Mohamed A,Wilson James P]
Ann Pharmacother.2002 Feb;36(2):288-95. PMID: 11847951

122: Cerivastatin and reports of fatal rhabdomyolysis.

[Staffa Judy A,Chang Jennie,Green Lanh]
N Engl J Med.2002 Feb 14;346(7):539-40. PMID: 11844864

123: [Safety profile of statins].

[Prieto J C]
Rev Med Chil.2001 Nov;129(11):1237-40. PMID: 11836874

124: [Rhabdomyolysis associated with combined treatment of cerivastatin and gemfibrozil].

[Bosch Rovira T,Llompart Pou J A,Forteza-Rey J]
Rev Clin Esp.2001 Dec;201(12):731-2. PMID: 11835892

125: Withdrawal of cerivastatin from the world market.

[Furberg Curt D,Pitt Bertram]
Curr Control Trials Cardiovasc Med.2001;2(5):205-207. PMID: 11806796

126: [Cerivastatin and acute kidney failure caused by rhabdomyolysis].

[Bravo J J,Novoa D,Romero R,Sánchez-Guisande D]
Nefrologia.2001 Sep-Oct;21(5):509. PMID: 11795023

127: [Rhabdomyolysis and anuric kidney failure induced by the treatment with a gemfibrozil-cerivastatin combination].

[Sirvent A E,Cabezuelo J B,Enríquez R,Amorós F,González C,Reyes A]
Nefrologia.2001 Sep-Oct;21(5):497-500. PMID: 11795020

128: Rhabdomyolysis and statin therapy: relevance to the elderly.

[Sica Domenic A,Gehr Todd W B]
Am J Geriatr Cardiol.2002 Jan-Feb;11(1):48-55. PMID: 11773716

129: [Myotoxicity and rhabdomyolisis due to statins].

[Banga J D]
Ned Tijdschr Geneeskd.2001 Dec 8;145(49):2371-6. PMID: 11770264

130: The withdrawal of Baycol (cerivastatin).

[Griffin J P]
Adverse Drug React Toxicol Rev.2001 Dec;20(4):177-80. PMID: 11770168

131: Statin-associated myopathy.

[Hamilton-Craig I]
Med J Aust.2001 Nov 5;175(9):486-9. PMID: 11758079

132: Case reports of rhabdomyolysis associated with cerivastatin therapy.

[Simpson S]
Arch Intern Med.2001 Nov 26;161(21):2630-1. PMID: 11718617

133: Another report of acute rhabdomyolysis following cerivastatin monotherapy.

[Milionis H J,Tsapoga T G,Elisaf M S]
Arch Intern Med.2001 Nov 26;161(21):2629-30. PMID: 11718615

134: Other reports of cerivastatin-induced rhabdomyolysis.

[Gabay M,Lodolce A]
Arch Intern Med.2001 Nov 26;161(21):2629. PMID: 11718614

135: Massive rhabdomyolysis and life threatening hyperkalaemia in a patient with the combination of cerivastatin and gemfibrozil.

[Hendriks F,Kooman J P,van der Sande F M]
Nephrol Dial Transplant.2001 Dec;16(12):2418-9. PMID: 11733637

136: Learning from the cerivastatin experience.

[Farmer J A]
Lancet.2001 Oct 27;358(9291):1383-5. PMID: 11705478

137: Safety of statins in the new millennium.

[Jukema J W,Lansberg P J]
Neth Heart J.2001 Nov;9(8):343-345. PMID: 25696757

138: Baycol: take-home messages about medications.

Harv Heart Lett.2001 Oct;12(2):2-3. PMID: 11684487

139: [Cerivastatin and gemfibrozil: a dangerous combination].

[Tormo Molina J,Gázquez Pérez I,Matas Hoces A]
Aten Primaria.2001 Oct 15;28(6):438-9. PMID: 11602128

140: [Rhabdomyolysis induced by cerivastatin].

[Hernanz Hernanz P,Rodríguez Hermida B,Sainza Rúa T,Ortega Inclán M N]
Aten Primaria.2001 Oct 15;28(6):438. PMID: 11602127

141: Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).

[Igel M,Sudhop T,von Bergmann K]
Eur J Clin Pharmacol.2001 Aug;57(5):357-64. PMID: 11599653

142: [Fatal rhabdomyolysis caused by cerivastatin].

[Scheen A J]
Rev Med Liege.2001 Aug;56(8):592-4. PMID: 11584446

143: Substituting for cerivastatin (Baycol).

Med Lett Drugs Ther.2001 Sep 17;43(1113):79-80. PMID: 11581579

144: Cerivastatin and gemfibrozil-associated rhabdomyolysis.

[Bruno-Joyce J,Dugas J M,MacCausland O E]
Ann Pharmacother.2001 Sep;35(9):1016-9. PMID: 11573847

145: Cerivastatin withdrawn from market.

[Thompson C A]
Am J Health Syst Pharm.2001 Sep 15;58(18):1685. PMID: 11571807

146: Bayer pulls cerivastatin (Baycol) from market.

[Wooltorton E]
CMAJ.2001 Sep 4;165(5):632. PMID: 11563216

147: [Severe rhabdomyolysis associated with cerivastatin and gemfibrozil].

[de Arriba Méndez J J,Gómez Merino E,Sáez Barcelona J A,Sáez Méndez L]
Med Clin (Barc).2001 Sep 15;117(7):278-9. PMID: 11562335

148: Rest easy, statin users. Benefits dwarf risks for these cholesterol drugs.

[Comarow A]
US News World Rep.2001 Sep 3;131(8):45. PMID: 11550394

149: Baycol withdrawn from market.

[SoRelle R]
Circulation.2001 Aug 21;104(8):E9015-6. PMID: 11521677

150: Bayer decides to withdraw cholesterol lowering drug.

[Charatan F]
BMJ.2001 Aug 18;323(7309):359. PMID: 11509419

151: Cerivastatin-induced rhabdomyolysis in a renal transplant on cyclosporin.

[Mora C,Rodríguez M L,Navarro J F]
Transplantation.2001 Aug 15;72(3):551. PMID: 11502997

152: Statin-fibrate combination therapy.

[Shek A,Ferrill M J]
Ann Pharmacother.2001 Jul-Aug;35(7-8):908-17. PMID: 11485144

153: Severe rhabdomyolysis associated with the cerivastin-gemfibrozil combination therapy: report of a case.

[Lau T K,Leachman D R,Lufschanowski R]
Tex Heart Inst J.2001;28(2):142-5. PMID: 11453128

154: [Rhabdomyolysis complicated with acute renal insufficiency in a patient treated with gemfibrozil and cerivastatin].

[Vascónez Espinosa F,Gómez Rodríguez N,Martín Joven A,Posada García F J]
Rev Clin Esp.2001 Apr;201(4):228-9. PMID: 11447919

155: Rhabdomyolysis due to cerivastatin monotherapy.

[Gemici G,Toprak A,Oktay A]
Am J Med.2001 Jun 15;110(9):742. PMID: 11417566

156: Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: is the interaction predictable?

[Tomlinson B,Lan I W]
Am J Med.2001 Jun 1;110(8):669-70. PMID: 11388340

157: Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia.

[Mastroianni C M,d'Ettorre G,Forcina G,Lichtner M,Corpolongo A,Coletta S,Vullo V]
AIDS.2001 Apr 13;15(6):820-1. PMID: 11371708

158: Cerivastatin-induced rhabdomyolisis in a patient with diabetic nephropathy.

[Marigliano N,Castellano I,Sánchez O,Covarsí A]
Am J Nephrol.2001 Jan-Feb;21(1):86. PMID: 11275641

159: Acute rhabdomyolysis associated with cerivastatin therapy.

[Garcia-Valdecasas-Campelo E,Gonzalez-Reimers E,Lopez-Lirola A,Rodriguez-Rodriguez E,Santolaria-Fernandez F]
Arch Intern Med.2001 Mar 26;161(6):893. PMID: 11268236

160: Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.

[Lee A J,Maddix D S]
Ann Pharmacother.2001 Jan;35(1):26-31. PMID: 11197581

161: Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.

[Plosker G L,Dunn C I,Figgitt D P]
Drugs.2000 Nov;60(5):1179-206. PMID: 11129127

162: [Undesirable drug interactions of hypolipemic drugs].

[Chojnowska-Jezierska J]
Pol Merkur Lekarski.2000 Sep;9(51):618-20. PMID: 11126989

163: Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil.

[Alexandridis G,Pappas G A,Elisaf M S]
Am J Med.2000 Aug 15;109(3):261-2. PMID: 11023440

164: Comparative tolerability of the HMG-CoA reductase inhibitors.

[Farmer J A,Torre-Amione G]
Drug Saf.2000 Sep;23(3):197-213. PMID: 11005703

165: A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report.

[Ozdemir O,Boran M,Gökçe V,Uzun Y,Koçak B,Korkmaz S]
Angiology.2000 Aug;51(8):695-7. PMID: 10959522

166: Influenza vaccine--a possible trigger of rhabdomyolysis induced acute renal failure due to the combined use of cerivastatin and bezafibrate.

[Plotkin E,Bernheim J,Ben-Chetrit S,Mor A,Korzets Z]
Nephrol Dial Transplant.2000 May;15(5):740-1. PMID: 10809833

167: Cerivastatin-induced rhabdomyolysis.

[Rodríguez M L,Mora C,Navarro J F]
Ann Intern Med.2000 Apr 4;132(7):598. PMID: 10744612

168: Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil.

[Bermingham R P,Whitsitt T B,Smart M L,Nowak D P,Scalley R D]
Am J Health Syst Pharm.2000 Mar 1;57(5):461-4. PMID: 10711527

169: New insights into the pharmacodynamic and pharmacokinetic properties of statins.

[Corsini A,Bellosta S,Baetta R,Fumagalli R,Paoletti R,Bernini F]
Pharmacol Ther.1999 Dec;84(3):413-28. PMID: 10665838

170: 'Fire and forget?' - pharmacological considerations in coronary care.

[Bottorff M]
Atherosclerosis.1999 Sep 9;147 Suppl 1:S23-30. PMID: 10575059

171: Dual hepatic metabolism of cerivastatin--clarifications.

[Guyton J R,Dujovne C A,Illingworth D R]
Am J Cardiol.1999 Aug 15;84(4):497. PMID: 10468102

172: Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy.

[Pogson G W,Kindred L H,Carper B G]
Am J Cardiol.1999 Apr 1;83(7):1146. PMID: 10190540

173: Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.

[Yee H S,Fong N T]
Ann Pharmacother.1998 Oct;32(10):1030-43. PMID: 9793596